Results 61 to 70 of about 16,658,609 (280)

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

Molecular Oncology
Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy strategy and has achieved satisfactory outcomes in the treatment of hematological malignancies.
Minmin Wang, Linzi Jia, Xiangpeng Dai, Xiaoling Zhang   +3 more
doaj   +1 more source

CAR-T cell therapy in nephrology

Renal Failure
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising immunotherapeutic strategy beyond oncology, offering new treatment opportunities for immune-mediated kidney diseases. These conditions including systemic lupus erythematosus, ANCA-associated vasculitis, membranous nephropathy, and monoclonal gammopathy-related ...
Tondolo, Francesco, Gessaroli, Elisa, Maritati, Federica, Colombini, Irene, Shkjau, Marinela, La Manna, Gaetano, Comai, Giorgia   +6 more
openaire   +4 more sources

Current strategies to improve CAR-T cell persistence [PDF]

Chimeric antigen receptor T (CAR-T) cell therapy has transformed the field of immunology by redirecting T lymphocytes toward tumor antigens. Despite successes in attaining remission rates as high as 70%, the performance of CAR therapy is limited by the ...
Soren, Ghorai, Ashley , Pearson
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Scientific Reports, 2022
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to
Li Li, Qing Li, Zi-Xun Yan, Ling-Shuang Sheng, Di Fu, Pengpeng Xu, Li Wang, Wei-Li Zhao   +7 more
doaj   +1 more source

The EBMT/EHA CAR-T Cell Handbook [PDF]

, 2022
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying ...

core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

CAR T- cell therapy: A promising novel approach for treatment of cancer

Cancer Treatment and Research Communications
Chimeric Antigen Receptor T-cell (CAR-T cell) therapy is a promising cancer treatment that has shown success in treating certain type of cancer. It has demonstrated remarkable efficacy, particularly in hematologic malignancies such as certain types of ...
Mahesh Kumar Posa, Jyoti Singh, Sadia Parveen, Subhranshu Panda   +3 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source